Skip to main content

Marina Lorente Picón

Institutions of which they are part

Predoctoral researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Marina Lorente Picón

Institutions of which they are part

Predoctoral researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Projects

Malalties neurodegeneratives

IP: Miquel Vila Bover
Collaborators: Jorge Hernández Vara, Joan Compte Barrón, Marta Martínez Vicente, Jordi Bove Badell, Eddie Pradas Gracia, Maria Camprodon Gomez, Marina Lorente Picón, Laura Castillo Ribelles, Oriol de Fabregues-Boixar Nebot, Javier Hoyo Pérez, Ariadna Laguna Tuset, Thais Cuadros Arasa, Jordi Riera Heredia, David Ramos Vicente, Marta Montpeyó Garcia-Moreno, Helena Xicoy Cortada, Malalties neurodegeneratives , Marta González Sepúlveda, Joana Margalida Cladera Sastre, Annabelle Parent, Daniela Samaniego Toro, Daniela Samaniego Toro
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 00784
Duration: 01/01/2022 - 30/06/2025

The brain-body axis in Parkinson’s disease patients: from pathophysiology to biomarkers and therapeutic approaches

IP: Ariadna Laguna Tuset
Collaborators: Maria Victoria Gonzalez Martinez, Miquel Vila Bover, Marina Lorente Picón, Helena Xicoy Cortada, Daniela Samaniego Toro, Daniela Samaniego Toro, Sara Belmonte Calderon
Funding agency: Instituto de Salud Carlos III
Funding: 171820
Reference: PI21/01603
Duration: 01/01/2022 - 30/06/2026

The Gut-Brain axis in Parkinson's disease: novel pathogenic mechanisms and new possibilities for biomarkers and therapeutic approaches

IP: Ariadna Laguna Tuset
Collaborators: Marina Lorente Picón, Helena Xicoy Cortada
Funding agency: Fundació "La Caixa"
Funding: 303300
Reference: 2018_INCOMING_CAIXA/LAGUNA
Duration: 02/10/2019 - 30/04/2023

Related news

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.

This initiative is part of a pioneering study that seeks to assess how the relationship between different age groups can influence the quality of life and mental health of patients.

Related professionals

Pablo Vilalta Gras

Pablo Vilalta Gras

Zelador/a
General Services and Infrastructures Unit
Manager
Read more
Carmen Sanchez Suarez

Carmen Sanchez Suarez

Molecular Medical Imaging
Read more
Laura Rubio Guerrero

Laura Rubio Guerrero

Medium Grade Technician
Purchase and Biddings Unit
Finance Directorate
Read more
Joana Ramis Garcia

Joana Ramis Garcia

Predoctoral researcher
Pharmacokinetic Nanoparticles
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.